Skip to main content

Illinois IGB

David Shapiro

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

November 21, 2023

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75% of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these advanced tumors.


November 21, 2023


Related Articles

Team identifies key driver of cancer cell death pathway that activates immune cells

July 31, 2023

Scientists have identified a protein that plays a critical role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers. They report their findings in the journal Cancer Research


July 31, 2023


Related Articles

Treatment of liver metastases in breast cancer patients improved by low-carb diets

March 28, 2022

A new study by Zeynep Madak-Erdogan (CGD/EIRH/GSP) Associate Professor of Food Science and Human Nutrition and Cancer Center at Illinois Education Program Leader, and her team have found a new mechanism of endocrine resistance in breast cancers metastasized to the liver.


March 28, 2022


Related Articles

New approach eradicates breast cancer in mice

July 21, 2021

A new approach to treating breast cancer kills 95-100% of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels.

Led by scientists at the University of Illinois Urbana-Champaign, the research team reports the findings in the journal Science Translational Medicine.


July 21, 2021


Related Articles

Cancer compound leads to major licensing deal

October 6, 2020

Researchers affiliated with the Cancer Center at Illinois and the IGB discovered a novel small molecule compound that is now the subject of a new global licensing agreement between the pharmaceutical company Bayer AG and the cancer drug development company Systems Oncology LLC. Systems Oncology originally licensed the IP related to the compound in 2018, and this new deal will now give Bayer the exclusive rights to develop the compound, currently called ERSO, as a cancer therapy.


October 6, 2020


Related Articles

Subscribe to David Shapiro